IPSC

SEC source: 0001062993-24-016641 · form4.xml · nonDerivative · entry 1

Quimi Daphne · CIK 0001543031 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.525 to $1.54. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001062993-24-014585 · form4.xml · nonDerivative · entry 1

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,163

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001062993-24-014582 · form4.xml · nonDerivative · entry 1

Carr Douglas · CIK 0001867173 · SVP Finance & Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 334,041

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001062993-24-014193 · form4.xml · nonDerivative · entry 1

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 274,933

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 9, 2024.

SEC source: 0001062993-24-014090 · form4.xml · nonDerivative · entry 2

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 275,519

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 9, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-24-014090 · form4.xml · nonDerivative · entry 1

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 277,119

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 9, 2024.

SEC source: 0001062993-24-012907 · form4.xml · derivative · entry 1

JIMENEZ JOSEPH · CIK 0001199095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001062993-24-012906 · form4.xml · derivative · entry 1

Walbert Timothy P · CIK 0001349376 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001062993-24-012905 · form4.xml · derivative · entry 1

Quimi Daphne · CIK 0001543031 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001062993-24-012904 · form4.xml · derivative · entry 1

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001062993-24-012903 · form4.xml · derivative · entry 1

Riva Alessandro · CIK 0001867172 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001062993-24-012902 · form4.xml · derivative · entry 1

Carlo Rizzuto · CIK 0001817033 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001062993-24-012900 · form4.xml · derivative · entry 1

Blackwell Kimberly · CIK 0001816465 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001062993-24-012992 · form4.xml · nonDerivative · entry 1

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 277,319

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 9, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.685 to $2.985, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-24-012312 · form4.xml · nonDerivative · entry 1

Carr Douglas · CIK 0001867173 · SVP Finance & Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 334,330

F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 100% on June 7, 2025, subject the Reporting Person's continued service through such vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

SEC source: 0001062993-24-012076 · form4.xml · nonDerivative · entry 1

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 282,319

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 9, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.895 to $3.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-24-010860 · form4.xml · nonDerivative · entry 1

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 287,319

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 9, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.86 to $3.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-24-009575 · form4.xml · nonDerivative · entry 1

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 292,319

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 9, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-24-009574 · form4.xml · nonDerivative · entry 1

Carr Douglas · CIK 0001867173 · SVP Finance & Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,323

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001062993-24-009573 · form4.xml · nonDerivative · entry 1

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,236

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001062993-24-008759 · form4.xml · nonDerivative · entry 1

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 297,319

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 9, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.98 to $3.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001062993-24-006058 · form4.xml · derivative · entry 6

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,655

Underlying: Common Stock · 22,831 shares

Expires 2029-07-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001062993-24-006058 · form4.xml · nonDerivative · entry 4

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,149

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.87 to $5.48, inclusive.

SEC source: 0001062993-24-006058 · form4.xml · nonDerivative · entry 3

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,980

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.

SEC source: 0001062993-24-006185 · form4.xml · derivative · entry 2

Carr Douglas · CIK 0001867173 · SVP Finance & Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2034-03-07

F2 · derivative.exercise_date: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

SEC source: 0001062993-24-006185 · form4.xml · nonDerivative · entry 1

Carr Douglas · CIK 0001867173 · SVP Finance & Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,580

F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

SEC source: 0001062993-24-006183 · form4.xml · derivative · entry 3

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,000

Underlying: Common Stock · 146,000 shares

Expires 2034-03-07

F2 · derivative.exercise_date: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

SEC source: 0001062993-24-006183 · form4.xml · nonDerivative · entry 1

Russotti Gregory · CIK 0001867305 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 302,319

F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

SEC source: 0001062993-24-006182 · form4.xml · derivative · entry 2

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,000

Underlying: Common Stock · 146,000 shares

Expires 2034-03-07

F2 · derivative.exercise_date: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

SEC source: 0001062993-24-006182 · form4.xml · nonDerivative · entry 1

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,149

F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

SEC source: 0001062993-24-006181 · form4.xml · derivative · entry 3

Levitsky Hyam · CIK 0001375792 · President of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,000

Underlying: Common Stock · 146,000 shares

Expires 2034-03-07

F2 · derivative.exercise_date: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

SEC source: 0001062993-24-006181 · form4.xml · nonDerivative · entry 1

Levitsky Hyam · CIK 0001375792 · President of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

SEC source: 0001062993-24-006667 · form4.xml · derivative · entry 2

Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,550

Underlying: Common Stock · 104,550 shares

Expires 2034-03-07

F2 · date: This Form 4 was originally filed under the incorrect Issuer on March 11, 2024 due to an administrative error (the "Original Form 4"). The Original Form 4 is being refiled to appear associated with the correct Issuer.

F3 · derivative.exercise_date: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

SEC source: 0001062993-24-006667 · form4.xml · nonDerivative · entry 1

Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,470,704

F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

F2 · date: This Form 4 was originally filed under the incorrect Issuer on March 11, 2024 due to an administrative error (the "Original Form 4"). The Original Form 4 is being refiled to appear associated with the correct Issuer.

SEC source: 0001062993-24-006058 · form4.xml · derivative · entry 5

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,486

Underlying: Common Stock · 30,684 shares

Expires 2029-07-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001062993-24-006058 · form4.xml · nonDerivative · entry 2

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,149

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.85 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.

SEC source: 0001062993-24-006058 · form4.xml · nonDerivative · entry 1

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,833

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.

SEC source: 0001062993-24-003878 · form4.xml · derivative · entry 3

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,170

Underlying: Common Stock · 485 shares

Expires 2029-07-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001062993-24-003878 · form4.xml · nonDerivative · entry 2

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,149

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.85 to $4.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-24-003878 · form4.xml · nonDerivative · entry 1

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,634

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.

SEC source: 0001062993-24-002321 · form4.xml · nonDerivative · entry 2

Carr Douglas · CIK 0001867173 · SVP Finance & Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,580

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001062993-24-002320 · form4.xml · nonDerivative · entry 2

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,149

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001062993-24-002321 · form4.xml · nonDerivative · entry 1

Carr Douglas · CIK 0001867173 · SVP Finance & Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,137

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001062993-24-002320 · form4.xml · nonDerivative · entry 1

Farid Adrienne · CIK 0001867310 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,933

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001062993-23-022023 · form4.xml · derivative · entry 3

Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 573,691

Underlying: Common Stock · 573,691 shares

Expires 2033-12-04

F3 · derivative.exercise_date: The option vests 25% on December 4, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

SEC source: 0001062993-23-022023 · form4.xml · nonDerivative · entry 2

Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,453,279

F2 · security: Reflects a grant of RSUs. The RSUs underlying this grant shall vest in full on December 4, 2024, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001062993-23-022023 · form4.xml · nonDerivative · entry 1

Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,173,775

F1 · security: Reflects a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs underlying this grant shall vest 25% on December 4, 2024, with the remaining 75% vesting in one-twelfth (1/12th) increments on each of the first trading days on or after each of February 15, May 15, August 15, and November 15, subject to the Reporting Person's continued service through each applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

SEC source: 0001062993-23-020090 · form4.xml · nonDerivative · entry 1

Carr Douglas · CIK 0001867173 · SVP Finance & Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,780

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

SEC source: 0001062993-23-020089 · form4.xml · nonDerivative · entry 1

Diem Michael Craig · CIK 0001497624 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,533

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

SEC source: 0001062993-23-014173 · form4.xml · derivative · entry 1

Carlo Rizzuto · CIK 0001817033 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2024-06-27

F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.